These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15944944)

  • 1. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection.
    Giannelli G; Antonaci S
    Histol Histopathol; 2005 Jul; 20(3):939-44. PubMed ID: 15944944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.
    Sepulveda-Crespo D; Resino S; Martinez I
    Drugs; 2021 Mar; 81(4):419-443. PubMed ID: 33400242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fibrosis and chronic viral hepatitis.
    Gutierrez-Reyes G; Gutierrez-Ruiz MC; Kershenobich D
    Arch Med Res; 2007 Aug; 38(6):644-51. PubMed ID: 17613356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase functions in hepatic injury and fibrosis.
    Roderfeld M
    Matrix Biol; 2018 Aug; 68-69():452-462. PubMed ID: 29221811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis.
    Böker KH; Pehle B; Steinmetz C; Breitenstein K; Bahr M; Lichtinghagen R
    Hepatogastroenterology; 2000; 47(33):812-9. PubMed ID: 10919037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis.
    Amiot L; Vu N; Rauch M; L'Helgoualc'h A; Chalmel F; Gascan H; Turlin B; Guyader D; Samson M
    J Hepatol; 2014 Feb; 60(2):245-52. PubMed ID: 24036009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in evaluating the status of hepatitis C infection based on the functional changes of hepatic stellate cells (Review).
    Wang W; Huang X; Fan X; Yan J; Luan J
    Mol Med Rep; 2020 Nov; 22(5):4116-4124. PubMed ID: 33000255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of toll-like receptors 2 and 4 mRNA expression in chronic hepatitis C virus infection.
    Shehata MA; Abou El-Enein A; El-Sharnouby GA
    Egypt J Immunol; 2006; 13(1):141-52. PubMed ID: 17974158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis.
    Costantini S; Capone F; Guerriero E; Maio P; Colonna G; Castello G
    Eur Cytokine Netw; 2010 Dec; 21(4):251-6. PubMed ID: 21081303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection.
    Bièche I; Asselah T; Laurendeau I; Vidaud D; Degot C; Paradis V; Bedossa P; Valla DC; Marcellin P; Vidaud M
    Virology; 2005 Feb; 332(1):130-44. PubMed ID: 15661146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue remodelling in liver diseases.
    Giannelli G; Quaranta V; Antonaci S
    Histol Histopathol; 2003 Oct; 18(4):1267-74. PubMed ID: 12973693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key Players of Hepatic Fibrosis.
    Dawood RM; El-Meguid MA; Salum GM; El Awady MK
    J Interferon Cytokine Res; 2020 Oct; 40(10):472-489. PubMed ID: 32845785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of cirrhosis is maintained by intrahepatic regulatory T cells that inhibit fibrosis resolution by regulating the balance of tissue inhibitors of metalloproteinases and matrix metalloproteinases.
    Zhang X; Feng M; Liu X; Bai L; Kong M; Chen Y; Zheng S; Liu S; Wan YJ; Duan Z; Han YP
    Transl Res; 2016 Mar; 169():67-79.e1-2. PubMed ID: 26613891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
    El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
    Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?
    Yi HS; Jeong WI
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():99-104. PubMed ID: 23855303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCL5: a double-edged sword in host defense against the hepatitis C virus.
    Katsounas A; Schlaak JF; Lempicki RA
    Int Rev Immunol; 2011; 30(5-6):366-78. PubMed ID: 22053974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Disease: HCV-induced liver injury.
    Mengshol JA; Golden-Mason L; Rosen HR
    Nat Clin Pract Gastroenterol Hepatol; 2007 Nov; 4(11):622-34. PubMed ID: 17978819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection Induces Transforming Growth Factor β1 Production through Glucose-Regulated Protein 94.
    Jee MH; Hong KY; Park JH; Lee JS; Kim HS; Lee SH; Jang SK
    J Virol; 2015 Dec; 90(6):3044-55. PubMed ID: 26719248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory status in human hepatic cirrhosis.
    Martínez-Esparza M; Tristán-Manzano M; Ruiz-Alcaraz AJ; García-Peñarrubia P
    World J Gastroenterol; 2015 Nov; 21(41):11522-41. PubMed ID: 26556984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic stellate cells and the reversal of fibrosis.
    Kisseleva T; Brenner DA
    J Gastroenterol Hepatol; 2006 Oct; 21 Suppl 3():S84-7. PubMed ID: 16958681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.